Evidence map›Paper›PMID 33477021›Full record

ArticleBioorganic & medicinal chemistry2021

Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools.

Tyler Scherzi, Elizabeth A D'Ambrosio, Samer S Daher, Catherine L Grimes, Paul M Dunman, Rodrigo B Andrade

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tyler ScherziDepartment of Microbiology and Immunology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, United States.
Elizabeth A D'AmbrosioDepartment of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716, United States.
Samer S DaherDepartment of Chemistry, Temple University, Philadelphia, PA 19122, United States.
Catherine L GrimesDepartment of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716, United States.
Paul M DunmanDepartment of Microbiology and Immunology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, United States.
Rodrigo B AndradeDepartment of Chemistry, Temple University, Philadelphia, PA 19122, United States. Electronic address: randrade@temple.edu.
Temple University · USUniversity of Delaware · USUniversity of Rochester · US

Funding

Synthesis and Evaluation of Narrow-Spectrum Antibiotics Targeting MRSAR01GM126221 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI VALENTINE, ANN M · 2018 to 2019
$762k
NIGMS NIH HHS R01 GM126221
6 · The paper itself

Abstract

Small molecule target identification is a critical step in modern antibacterial drug discovery, particularly against multi-drug resistant pathogens. Albocycline (ALB) is a macrolactone natural product with potent activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) whose mechanism of action has been elusive to date. Herein, we report biochemical and genomic studies that reveal ALB does not target bacterial peptidoglycan biosynthesis or the ribosome; rather, it appears to modulate NADPH ratios and upregulate redox sensing in the cell consistent with previous studies at Upjohn. Owing to the complexity inherent in biological pathways, further genomic assays are needed to identify the true molecular target(s) of albocycline.

Indexed as

Anti-Bacterial AgentsDose-Response Relationship, DrugLactonesMethicillin ResistanceMicrobial Sensitivity TestsMolecular StructureNADPStaphylococcus aureusStructure-Activity RelationshipVancomycin ResistancealbocyclineAnti-Bacterial AgentsLactonesNADPAlbocyclineDissociation constantsMechanism of actionMurANADPHResistant mutantsRibosomeSequencing

Identifiers

PMID33477021
PMCPMC7891091
OpenAlexW3119562779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.